TY  - CHAP
M1  - Book, Section
TI  - Drug Literature Evaluation I: Controlled Clinical Trial Evaluation
A1  - Phillips, Jennifer
A1  - Sheehan, Amy Heck
A1  - Gettig, Jacob
A1  - Kendrach, Michael G.
A2  - Malone, Patrick M.
A2  - Witt, Benjamin A.
A2  - Malone, Meghan J.
A2  - Peterson, David M.
PY  - 2022
T2  - Drug Information: A Guide for Pharmacists, 7e
AB  - Learning  ObjectivesAfter  completing  this  chapter,  the  reader  will  be  able  to:Identify  skills  health  care  practitioners  need  to  evaluate  medical  literature  and  apply  it  to  patient  care.Describe  special  characteristics  of  a  controlled  clinical  trial  that  distinguish  this  research  design  as  the  prototype  for  clinical  research.Prepare  a  null  hypothesis  (H0)  based  upon  the  clinical  trial  objective(s)  and  endpoint(s).Differentiate  between  the  types  of  data,  measures  of  central  tendency,  and  measures  of  variability.Differentiate  between  Type  I  and  Type  II  errors;  discuss  methods  to  reduce  the  possibility  of  either  of  these  errors  occurring.Interpret  p  values  and  95%  confidence  interval  (CI);  discuss  whether  to  reject  or  fail-to-reject  the  H0  by  using  these  clinical  trial  results.Calculate  and  interpret  relative  risk  (RR),  relative  risk  reduction  (RRR),  absolute  risk  reduction  (ARR),  and  number  needed  to  treat  (NNT).State  whether  statistical  significance  and  clinical  difference  are  present  using  the  clinical  trial  results.Explain  the  purpose  and  usage  of  editorials,  letters  to  the  editor,  and  secondary  journals  in  critiquing  clinical  trials  and  the  application  of  results  into  practice.Identify  key  features  of  adaptive  clinical  trials  and  noninferiority  trials.  
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/04/25
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1190459106
ER  -